A Phase III trial of Avastin (bevacizumab) in breast cancer met its primary endpoint of improving progression-free survival (PFS), but analysts remained split on whether the new data would be enough to gain FDA approval. (BioWorld Today)

A Phase III trial of Avastin (bevacizumab) in breast cancer met its primary endpoint of improving progression-free survival (PFS), but analysts remained split on whether the new data would be enough to gain FDA approval. (BioWorld Today)

BioNumerik Pharmaceuticals Inc. started a pivotal Phase III trial comparing Karenitecin (BNP1350) with GlaxoSmithKline plc's Hycamtin (topotecan) in relapsed ovarian cancer. (BioWorld Today)

BioNumerik Pharmaceuticals Inc. started a pivotal Phase III trial comparing Karenitecin (BNP1350) with GlaxoSmithKline plc's Hycamtin (topotecan) in relapsed ovarian cancer. (BioWorld Today)